Broker Research

Brigade Enterprises (BEL) reported earnings of Rs717mn in 4QFY19, up 21% QoQ. The earnings growth was driven by: 1) Revenue growth of 11% QoQ and 75% YoY.
May 9, 2019, 11:30 a.m.
Publisher: nirmalbang.com

Gillette India’s (GILL) earnings in 3QFY19 continued to display volatility and unlike the previous quarter, top-line delivery was somewhat short of expectation, especially on account of the oral care segment.
May 9, 2019, 11:30 a.m.
Publisher: nirmalbang.com

Earning per share (EPS) of the company for the earnings for FY20E and FY21E is seen at Rs. 57.58 and Rs. 65.21 respectively. Net Sales of the company is expected to grow at a CAGR of 14% over 2018 to 2021E, respectively.
May 8, 2019, 12:11 p.m.
Author : Firstcall India Equity | Publisher: indianotes.com

Earning per share (EPS) of the company for the earnings for FY20E and FY21E is seen at Rs. 53.35 and Rs. 59.01 respectively. Net Sales and PAT of the company are expected to grow at a CAGR of 10% and 12% over 2018 to 2021E respectively.
May 8, 2019, 12:01 p.m.
Author : Firstcall India Equity | Publisher: indianotes.com

We have maintained our earnings estimates and the stock is trading at 50/41x CY19/CY20E earnings. 1QCY19 numbers of ABB were ahead of our and street expectations, both on the topline and bottom-line led by strong revenue performance across the segments.
May 8, 2019, 11:42 a.m.
Publisher: plindia.com

We downgrade CEAT from ‘Accumulate’ to ‘Hold’ owing to concerns regarding volume growth as well as margins. CEAT’s Q4FY19 consolidated operating margins stood at 9.2%, down by 250bps YoY / up by 100bps QoQ missed our expectations of 10.5%.
May 8, 2019, 11:31 a.m.
Publisher: plindia.com

We maintain positive stance on Titan post 4Q results given 1) the guidance of 20% jewellery sales growth in FY20 2) expected gains from backward integration and proactive strategy in Eyewear.
May 8, 2019, 11:31 a.m.
Publisher: plindia.com

During Q1CY19 MHCIE reported mixed bag numbers. Going forward Management expects its Indian operations to remain steady during H1CY19 and international operations to be robust.
May 8, 2019, 11:29 a.m.
Publisher: ws.karvyonline.com

Sanofi India’s (SIL) revenues in 1QCY19 stood at Rs7,173mn, above our/consensus estimate by 2.9%/3.3%, respectively. Revenues grew 16.1% YoY and decreased 1.3% QoQ.
May 8, 2019, 11:13 a.m.
Publisher: nirmalbang.com

With three European and two US approvals in place, Biocon is in the first row when the monetisation cycle of biosimilars began. Looking ahead, we expect the biosimilars will penetrate faster in the US healthcare industry with rising interest to adopt biosimilars.
May 7, 2019, 11:47 a.m.
Publisher: ashikagroup.com